Table 1.
Variable | n (%) | PNI | P value | |
---|---|---|---|---|
<47.2, n (%) | ≥47.2, n (%) | |||
Age (years) | 0.066 | |||
≤50 | 125 (52.7) | 65 (47.4) | 60 (60.0) | |
>50 | 112 (47.3) | 72 (52.6) | 40 (40.0) | |
Stage | <0.001 | |||
FIGO I | 28 (11.8) | 8 (5.8) | 20 (20.0) | |
FIGO II | 39 (16.5) | 15 (10.9) | 24 (24.0) | |
FIGO III | 140 (59.1) | 92 (67.2) | 48 (48.0) | |
FIGO IV | 30 (12.7) | 22 (16.1) | 8 (8.0) | |
Residual tumor mass | <0.001 | |||
≤2 cm | 132 (55.7) | 62 (45.3) | 70 (70.0) | |
>2 cm | 105 (44.3) | 75 (54.7) | 30 (30.0) | |
Histological subtype | 0.001 | |||
Serous | 123 (51.9) | 61 (44.5) | 62 (62.0) | |
Non-serous | 86 (36.3) | 63 (45.9) | 23 (23.0) | |
Histological grade | 0.237 | |||
G1 | 79 (33.3) | 40 (30.0) | 39 (39.0) | |
G2 | 52 (21.9) | 30 (21.9) | 22 (22.0) | |
G3 | 88 (37.1) | 56 (40.9) | 32 (32.0) | |
Ascites | <0.001 | |||
Negative | 102 (43.0) | 34 (24.8) | 68 (68.0) | |
Positive | 135 (57.0) | 103 (75.2) | 32 (32.0) | |
CA-125 (U/ml) | <0.001 | |||
<35 | 26 (11.0) | 5 (3.6) | 21 (21.0) | |
≥35 | 183 (77.2) | 117 (85.4) | 66 (66.6) | |
Chemosensitivity | <0.001 | |||
Sensitive | 131 (55.3) | 61 (44.5) | 70 (70.0) | |
Resistant | 106 (44.7) | 76 (55.5) | 30 (30.0) | |
CAR | <0.001 | |||
<0.5 | 142 (59.9) | 59 (43.1) | 83 (83.0) | |
≥0.5 | 95 (40.1) | 78 (56.9) | 17 (17.0) | |
LMR | <0.001 | |||
<3.82 | 132 (55.7) | 106 (77.4) | 26 (26.0) | |
≥3.82 | 105 (44.3) | 31 (22.6) | 74 (74.0) | |
mGPS | <0.001 | |||
0 | 97 (40.9) | 27 (19.7) | 70 (70.0) | |
1 | 76 (32.1) | 46 (33.6) | 30 (30.0) | |
2 | 64 (27.0) | 64 (46.7) | 0 (0.0) | |
BMI (kg/m2) | 0.460 | |||
<18.5 | 31 (13.1) | 20 (14.6) | 11 (11.0) | |
≥18.5 | 206 (86.9) | 117 (85.4) | 89 (89.0) |
CAR, C-reactive protein/albumin ratio; BMI, body mass index; FIGO, Federation of Gynecologists and Obstetricians; LMR, lymphocyte/monocyte ratio; mGPS, modified Glasgow prognostic score; PNI, prognostic nutritional index.